{
    "clinical_study": {
        "@rank": "58882", 
        "acronym": "TRIPLE 4", 
        "arm_group": [
            {
                "arm_group_label": "CHF5993 pMDI + Spacer", 
                "arm_group_type": "Experimental", 
                "description": "CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using Aerochamber Plus Flow-vu VHC spacer"
            }, 
            {
                "arm_group_label": "CHF5993 pMDI", 
                "arm_group_type": "Active Comparator", 
                "description": "CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using standard actuator only"
            }, 
            {
                "arm_group_label": "Placebo pMDI", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo pMDI x 4 inhalations"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is performed to investigate the effect of the spacing device on the\n      pharmacokinetics of CHF 5993 pMDI active ingredients administered with and without\n      Aerochamber Plus Flow-vu antistatic VHC spacer as a single administration in COPD patients.\n      Moreover, the general safety and tolerability of the treatments will be evaluated."
        }, 
        "brief_title": "Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": "Pulmonary Disease, Chronic Obstructive"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  COPD patients\n\n          -  smokers or ex-smokers\n\n          -  post-bronchodilator FEV1 between 30 and 60% of predicted value\n\n        Exclusion Criteria:\n\n          -  Positive serology to HIV and hepatitis\n\n          -  Known respiratory disorder other than COPD\n\n          -  Recent COPD exacerbations or hospitalization for COPD\n\n          -  Treatment with non-permitted concomitant medication\n\n          -  clinically relevant concomitant disease\n\n          -  clinically relevant abnormal laboratory or ECG parameters"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119234", 
            "org_study_id": "CCD-05993AA1-04", 
            "secondary_id": "2013-003770-27"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CHF5993 pMDI + Spacer", 
                    "CHF5993 pMDI"
                ], 
                "intervention_name": "Beclometasone/formoterol/glycopyrrolate", 
                "intervention_type": "Drug", 
                "other_name": "CHF5993 pMDI"
            }, 
            {
                "arm_group_label": "Placebo pMDI", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Beclomethasone", 
                "Formoterol", 
                "Glycopyrrolate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lodz", 
                    "country": "Poland", 
                    "state": "ul. Kopci\u0144skiego 22", 
                    "zip": "90-153"
                }, 
                "name": "Medical University in Lodz"
            }, 
            "investigator": {
                "last_name": "Piotr Kuna, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "3", 
        "official_title": "Open-label, Randomized, 3-way Cross-over, Placebo Controlled, Single Dose Clinical Pharmacology Study in COPD Patients After Inhalation of CHF 5993 pMDI Using the Standard Actuator With or Without AeroChamber Plus Flow-Vu VHC Spacer", 
        "overall_contact": {
            "email": "s.collarini@chiesi.com", 
            "last_name": "Sara Collarini, MSc", 
            "phone": "+39 0521 279 948"
        }, 
        "overall_official": {
            "affiliation": "Medical University Lodz", 
            "last_name": "Piotr Kuna, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "AUCt (up to the last quantifiable concentration) and Cmax (maximum concentration) from plasma concentrations vs time profiles.\nover 24h for formoterol and B17MP, over 48h for glycopyrrolate", 
            "measure": "Area under the curve of B17MP, formoterol and glycopyrrolate", 
            "safety_issue": "No", 
            "time_frame": "Over 24 and 48h after single administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119234"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "B17MP AUC0-30min, AUC0-24h, AUCinf, tmax, half-life Formoterol AUC0-30min, AUC0-24h, AUCinf, tmax, half-life Glycopyrrolate AUC0-30min, AUC0-48h, AUCinf, tmax, half-life", 
                "measure": "Other pharmacokinetic parameters for formoterol, glycopyrrolate and B17MP in plasma", 
                "safety_issue": "No", 
                "time_frame": "over 24 or 48h after single administration"
            }, 
            {
                "description": "from the signature of the informed consent until the follow-up phone call", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "over a period of 6 to 11 weeks"
            }, 
            {
                "description": "FEV1", 
                "measure": "Lung function", 
                "safety_issue": "Yes", 
                "time_frame": "30 min after single administration"
            }, 
            {
                "description": "cortisol AUC0-24h, Cmin and tmin", 
                "measure": "plasma cortisol", 
                "safety_issue": "Yes", 
                "time_frame": "over 24 h after single administration"
            }, 
            {
                "description": "cortisol excretion corrected and not corrected for creatinine", 
                "measure": "cortisol urinary excretion", 
                "safety_issue": "Yes", 
                "time_frame": "over 24 h after single administration"
            }, 
            {
                "description": "potassium AUC0-24h, tmin and Cmin", 
                "measure": "potassium plasma profile", 
                "safety_issue": "Yes", 
                "time_frame": "over 24 h after single administration"
            }, 
            {
                "description": "systolic and diastolic blood pressure", 
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "over 24 h after single administration"
            }, 
            {
                "description": "extracted from holter recording HR, QTcF, PR and QRS", 
                "measure": "ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "over 24 h after single administration"
            }
        ], 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}